EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nonsteroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Mechanistic Basis, Clinical Evidence, and Therapeutic Integration

Rami A Al-Horani, Navneet Goyal

Drugs and Drug Candidates · 28.05.2026 · 5 (2) · 33

DOI: 10.3390/ddc5020033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drugs and Drug Candidates, online erschienen am 28.05.2026. Verfasst von Rami A Al-Horani und 1 weiteren Autor:innen. Beteiligte Einrichtung: Colleges of Pharmacy & Arts and Sciences, Xavier University of Louisiana, New Orleans, LA 70125, USA. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The therapeutic landscape for heart failure (HF), particularly in patients with mildly reduced (HFmrEF) and preserved ejection fraction (HFpEF), has historically been characterized by limited effective disease-modifying options. The recent approval of nonsteroidal mineralocorticoid receptor antagonists (nsMRAs), specifically finerenone, represents a major paradigm shift. This review synthesizes contemporary evidence, including the landmark FINEARTS-HF trial, which demonstrated significant reductions in cardiovascular death and heart failure hospitalizations in patients with left ventricular ejection fraction (LVEF) ≥ 40%. These findings contrast with the neutral overall results and subgroup limitations observed with steroidal MRAs such as spironolactone in the TOPCAT trial. Mechanistic distinctions, cardiorenal benefits, and emerging metabolic effects of finerenone are explored alongside its complementary role with sodium–glucose cotransporter-2 (SGLT2) inhibitors. Practical considerations for implementation, including patient selection, dosing, monitoring, and combination therapy strategies, are discussed. Overall, nsMRAs establish a new foundation for the management of HFmrEF and HFpEF and represent a critical advancement in contemporary heart failure therapeutics.

Schlagwörter

Stichwörter der Autor:innen

HFmrEFHFpEFSGLT2 inhibitorscardiorenal syndromefinerenoneheart failurenonsteroidal mineralocorticoid receptor antagonists

Autor:innen und Institutionen

  • Colleges of Pharmacy & Arts and Sciences, Xavier University of Louisiana, New Orleans, LA 70125, USA.

Förderung

  • NIGMS NIH HHS
  • National Institute of General Medical Sciences

Zitieren

APA

Al-Horani, R. A., & Goyal, N. (2026). Nonsteroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Mechanistic Basis, Clinical Evidence, and Therapeutic Integration. Drugs and Drug Candidates, 5(2), 33. https://doi.org/10.3390/ddc5020033

Vancouver

Al-Horani RA, Goyal N. Nonsteroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Mechanistic Basis, Clinical Evidence, and Therapeutic Integration. Drugs and Drug Candidates. 2026;5(2):33. doi:10.3390/ddc5020033

BibTeX
@article{AlHorani2026,
  author = {Al-Horani, Rami A and Goyal, Navneet},
  title = {Nonsteroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Mechanistic Basis, Clinical Evidence, and Therapeutic Integration},
  journal = {Drugs and Drug Candidates},
  year = {2026},
  volume = {5},
  number = {2},
  pages = {33},
  doi = {10.3390/ddc5020033}
}
Kostenlos starten →